Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cot inhibitor-2 is a cot (Tpl2/MAP3K8) inhibitor (IC50: 1.6 nM) with potency, selectivity and oral activity. cot inhibitor-2 inhibits LPS-stimulated TNF-α production in human whole blood with an IC50 of 0.3 μM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 93.00 | |
2 mg | In stock | $ 137.00 | |
5 mg | In stock | $ 227.00 | |
10 mg | In stock | $ 367.00 | |
25 mg | In stock | $ 757.00 | |
50 mg | In stock | $ 1,330.00 | |
100 mg | In stock | $ 2,190.00 | |
500 mg | In stock | $ 4,380.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 268.00 |
Description | Cot inhibitor-2 is a cot (Tpl2/MAP3K8) inhibitor (IC50: 1.6 nM) with potency, selectivity and oral activity. cot inhibitor-2 inhibits LPS-stimulated TNF-α production in human whole blood with an IC50 of 0.3 μM. |
Targets&IC50 | TNF-α production (human whole blood):0.3 μM, Cot (Tpl2/MAP3K8):1.6 nM |
In vivo |
Cot inhibitor-2 (100 mg/kg ; orally ; rats) showed a Cmax of 517 ng/mL (0.89 μM) and AUC of 4841 ng•h/mL.[1] Cot inhibitor-2 (25 mg/kg ; p.o. ; rats) is tested in the LPS-induced TNF-α production model in female Sprague-Dawley rats that Cot inhibitor-2 inhibits LPS-induced TNF-α production by 83%.[1] |
Molecular Weight | 539.43 |
Formula | C26H25Cl2FN8 |
CAS No. | 915363-56-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 36.0 mg/mL (66.7 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cot inhibitor-2 915363-56-3 Apoptosis MAPK TNF Cot inhibitor2 Cot inhibitor 2 inhibitor inhibit